Mega Genomics

Mega Genomics ROA

The Return on Assets (ROA) of Mega Genomics (6667.HK) as of Oct 16, 2026 is 3.16 %. In the previous year, Return on Assets (ROA) was 6.10 % — a change of -48.16% (lower).

ROA

3.16 %

YoY

-48.16%

Last updated:

In 2025, Mega Genomics's return on assets (ROA) was 3.16 %, a -48.16% increase from the 6.10 % ROA in the previous year.

The Mega Genomics ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
11.26 CNY
Jan 1, 2020
17.44 CNY
Jan 1, 2021
8.77 CNY
Jan 1, 2022
-2.14 CNY
Jan 1, 2023
3.77 CNY
Jan 1, 2024
6.10 CNY
Jan 1, 2025
3.16 CNY
The Mega Genomics ROA history
YEARROAYoY
3.16 %-48.16%
6.10 %+61.75%
3.77 %-276.20%
-2.14 %-124.40%
8.77 %-49.70%
17.44 %+54.91%
11.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mega Genomics Stock analysis

What does Mega Genomics do? Mega Genomics Ltd, listed on the Hong Kong Stock Exchange under ticker 6667.HK with ISIN KYG5960G1047, is a health care company headquartered in Beijing, China. The company, which went public on June 22, 2022, employs 267 full-time staff. Mega Genomics operates as a genetic testing platform, offering consumer genetic testing and cancer screening services. Its business is structured into three segments. The Consumer Genetic Testing Services segment provides tests related to nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, pharmacogenetic testing, and infectious disease testing. The Cancer Screening Services segment offers specific tests including the Septin9 colorectal cancer screening test, Syndecan-2 (SDC2) colorectal cancer screening test, and the ring finger protein 180 (RNF180)/Septin9 gastric cancer screening test. The Other Services segment delivers genetic research and analysis services to third-party research institutions. The company's website is https://www.megagenomics.cn/. Mega Genomics focuses on providing genetic testing solutions for both consumer and clinical applications, with an emphasis on cancer-related screening and personalized health assessments. The company's operations are based in Beijing, reflecting its position within China's growing health care sector. As a publicly traded entity, Mega Genomics is subject to the regulatory requirements of the Hong Kong Stock Exchange. Mega Genomics is one of the most popular companies on Eulerpool.

ROA Details

Understanding Mega Genomics's Return on Assets (ROA)

Mega Genomics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Mega Genomics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Mega Genomics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Mega Genomics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Mega Genomics stock

Return on Assets (ROA) of Mega Genomics is 3.16 % in 2025.

Return on Assets (ROA) of Mega Genomics changed from 6.10 % to 3.16 %, representing a -48.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Mega Genomics since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Mega Genomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Mega Genomics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Mega Genomics